<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Spring Builders: Rohit Pujari</title>
    <description>The latest articles on Spring Builders by Rohit Pujari (@rohit_pujari_7f35d57dfc70).</description>
    <link>https://springbuilders.dev/rohit_pujari_7f35d57dfc70</link>
    <image>
      <url>https://springbuilders.dev/images/pxrzfP3FbFR_olW3WfQwsAgpNg_abV7L9DlZ-iQDmiU/rs:fill:90:90/g:sm/mb:500000/ar:1/aHR0cHM6Ly9zcHJp/bmdidWlsZGVycy5k/ZXYvdXBsb2Fkcy91/c2VyL3Byb2ZpbGVf/aW1hZ2UvODc4MS83/ZDJmNTQ0Ni1hZThh/LTQ3YjYtYjcyOC05/MmJkZWQ2MTk2ZmMu/cG5n</url>
      <title>Spring Builders: Rohit Pujari</title>
      <link>https://springbuilders.dev/rohit_pujari_7f35d57dfc70</link>
    </image>
    <atom:link rel="self" type="application/rss+xml" href="https://springbuilders.dev/feed/rohit_pujari_7f35d57dfc70"/>
    <language>en</language>
    <item>
      <title>Robot End Effector Market Size, Share and Growth Forecast 2026-2034</title>
      <dc:creator>Rohit Pujari</dc:creator>
      <pubDate>Mon, 16 Nov 2026 09:27:39 +0000</pubDate>
      <link>https://springbuilders.dev/rohit_pujari_7f35d57dfc70/robot-end-effector-market-size-share-and-growth-forecast-2026-2034-3bkk</link>
      <guid>https://springbuilders.dev/rohit_pujari_7f35d57dfc70/robot-end-effector-market-size-share-and-growth-forecast-2026-2034-3bkk</guid>
      <description>&lt;p&gt;Market Overview:&lt;/p&gt;

&lt;p&gt;According to IMARC Group’s latest research publication, “Robot End Effector Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034”, The global robot end effector market size was valued at USD 3.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 10.3 Billion by 2034, exhibiting a CAGR of 11.55% from 2026-2034.&lt;/p&gt;

&lt;p&gt;This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.&lt;/p&gt;

&lt;p&gt;How AI is Reshaping the Future of the Robot End Effector Market&lt;/p&gt;

&lt;p&gt;AI integration in robot end effectors enables more precise handling, improved adaptability, and enhanced decision-making capabilities, allowing robots to perform complex tasks autonomously while reducing human intervention across industrial applications.&lt;br&gt;
In January 2025, the US President declared private sector spending of up to USD 500 Billion to support AI infrastructure, with the goal of surpassing competitor nations in the technology sector, directly accelerating the adoption of AI-powered robotic end effectors.&lt;br&gt;
Companies like ABB revealed the OmniCore platform featuring built-in AI and sensor technologies, reducing power usage by as much as 20% while improving automation precision in complex operations.&lt;br&gt;
The global AI market reached USD 115.62 Billion in 2024, and its rapid expansion is directly translating into smarter robot end effectors capable of adaptive gripping and autonomous material handling across logistics, manufacturing, and healthcare.&lt;br&gt;
Government-supported Industry 4.0 initiatives across Asia-Pacific and Europe are encouraging manufacturers to integrate intelligent end effectors into smart factory ecosystems, with India targeting 80 Million EVs on its roads by 2030, driving parallel demand for specialized robotic tooling.&lt;br&gt;
Download a sample PDF of this report: &lt;a href="https://www.imarcgroup.com/robot-end-effector-market/requestsample"&gt;https://www.imarcgroup.com/robot-end-effector-market/requestsample&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Key Trends in the Robot End Effector Market&lt;br&gt;
Increasing Demand for Flexible Automation: Industries are shifting toward robots capable of performing multiple tasks using interchangeable end effectors, allowing companies to streamline operations and adapt quickly to varying production needs. In August 2024, ATI Industrial Automation unveiled the GBX 10 Gigabit Ethernet Tool Changer Module, enhancing robotic flexibility by supporting fast data transfer and enabling seamless tool changes, reducing downtime and boosting operational efficiency in manufacturing and logistics. The global logistics market is projected to attain USD 8.1 Trillion by 2033, underscoring the scale of demand for flexible robotic systems.&lt;br&gt;
Advancements in AI-Oriented Robot End Effectors: Modern robot end effectors are becoming increasingly intelligent through the integration of AI and machine learning, enabling greater precision, improved adaptability, and enhanced autonomous decision-making. In March 2024, Agility Robotics introduced Agility Arc, a cloud automation platform that enhances robotic fleet management and streamlines end effector operations in logistics and manufacturing, simplifying deployment and system integration at scale.&lt;br&gt;
Growth in Precision Tasks Across Industries: The expansion of precision-intensive applications in automotive, healthcare, and electronics manufacturing is fueling the need for high-performance end effectors. Robotic-assisted surgeries in the United States have demonstrated a 77% reduction in blood clot occurrences and a 52% decrease in readmission risk compared to open surgery, according to the NIH, highlighting the critical role of precision robotic grippers and force-sensitive end effectors in healthcare.&lt;br&gt;
Rise of Collaborative Robots in SMEs: The growing adoption of collaborative robots (cobots) in small and medium-sized enterprises is driving demand for flexible, adaptive grippers that can safely operate alongside human workers. As cobots become more affordable and accessible, SMEs across manufacturing and food processing are deploying them for assembly, packaging, and quality control tasks, expanding the addressable market for end effector solutions.&lt;br&gt;
E-Commerce Expansion Accelerating Warehouse Automation: The burgeoning growth of online retail is pushing warehouses and fulfillment centers to adopt robotic grippers and suction cups for faster sorting, packaging, and material handling. The Europe e-commerce market is projected to hit USD 8.46 Trillion by 2033, while Brazil’s e-commerce sector and Mexico’s online retail market are both expanding rapidly, creating significant demand for robotic end effectors in regional fulfillment infrastructure.&lt;br&gt;
The robot end effector market report provides a comprehensive overview of the industry. This analysis is essential for stakeholders aiming to navigate the complexities of the biochar market and capitalize on emerging opportunities. &lt;/p&gt;

&lt;p&gt;Growth Factors in the Robot End Effector Market&lt;br&gt;
Industrial Automation Across Manufacturing Sectors: As manufacturing continues to integrate robotics for assembly, welding, and material handling, the demand for advanced end effectors is rising consistently. In India, 25.9 Million vehicles were manufactured and over 4.76 Million automobiles were exported in FY23, while Japan recorded 3,448,272 new passenger car sales in 2022, illustrating the automotive industry’s scale and its dependence on robotic end effectors for quality and speed.&lt;br&gt;
Electric Vehicle Production Driving Specialized Tooling Demand: The shift toward EVs is creating substantial demand for robotic end effectors capable of handling battery components and lightweight materials. India aims to achieve 30% EV penetration in private cars, 70% in commercial vehicles, and 80% in two-wheelers and three-wheelers by 2030, representing a compelling demand catalyst for specialized robotic grippers and tool changers across battery assembly lines.&lt;br&gt;
Healthcare Sector Investments in Robotic Precision: Hospitals and medical device manufacturers are increasingly investing in robotic-assisted surgical systems and laboratory automation, requiring high-precision end effectors with force-sensing capabilities. The documented clinical benefits of robotic surgery, including a 52% reduction in readmission risk, are driving hospitals in North America and Europe to expand their robotic surgery programs and upgrade associated tooling.&lt;br&gt;
Renewable Energy Projects Expanding Robotic Applications in MEA: The Middle East and Africa are investing heavily in renewable energy infrastructure, with the IEA reporting that energy investments in the Middle East reached USD 175 Billion in 2024, of which approximately 15% was directed toward renewable energy. Solar panel manufacturing and installation in the region are increasingly relying on precision robotic grippers, expanding the application scope for end effectors beyond traditional industrial settings.&lt;br&gt;
Government AI and Robotics Investment Unlocking New Adoption: Public sector commitments to AI infrastructure and domestic robotics manufacturing are accelerating the uptake of advanced end effectors. The US government’s facilitation of USD 500 Billion in private AI infrastructure spending, combined with Asia-Pacific government programs supporting smart factories and domestic robotics R&amp;amp;D, is enabling faster integration of next-generation end effectors across multiple industries.&lt;br&gt;
Leading Companies Operating in the Global Robot End Effector Industry:&lt;/p&gt;

&lt;p&gt;ABB Ltd.&lt;br&gt;
Applied Robotics Inc.&lt;br&gt;
ATI Industrial Automation Inc.&lt;br&gt;
Bastian Solutions LLC (Toyota Industries Corporation)&lt;br&gt;
Festo Beteiligungen GmbH and Co. KG&lt;br&gt;
FIPA Inc.&lt;br&gt;
KUKA Aktiengesellschaft (Midea Group Co. Ltd.)&lt;br&gt;
Schmalz-International GmbH&lt;br&gt;
SMC Corporation&lt;br&gt;
Soft Robotics Inc.&lt;br&gt;
Weiss Robotics GmbH and Co KG&lt;br&gt;
Zimmer Group GmbH&lt;br&gt;
Robot End Effector Market Report Segmentation:&lt;/p&gt;

&lt;p&gt;Breakup By Product:&lt;/p&gt;

&lt;p&gt;Welding Guns&lt;br&gt;
Grippers&lt;br&gt;
Suction Cups&lt;br&gt;
Clamps&lt;br&gt;
Tool Changers&lt;br&gt;
Others&lt;br&gt;
Grippers account for 37.6% of the market share in 2025, driven by their versatility across handling, assembling, and packaging applications in manufacturing, logistics, and healthcare. Their compatibility with collaborative robots and adaptability to objects of varying shapes and textures make them the preferred product type.&lt;/p&gt;

&lt;p&gt;Breakup By Application:&lt;/p&gt;

&lt;p&gt;Handling&lt;br&gt;
Assembling&lt;br&gt;
Welding&lt;br&gt;
Dispensing&lt;br&gt;
Painting&lt;br&gt;
Others&lt;br&gt;
Handling dominates with a 48.0% market share, as it represents the most widely deployed function across warehouses, manufacturing plants, and fulfillment centers. Robotic arms equipped with grippers and suction cups enable faster sorting, packaging, and material transportation, reducing labor costs and improving production efficiency.&lt;/p&gt;

&lt;p&gt;Breakup By End Use Industry:&lt;/p&gt;

&lt;p&gt;Automotive&lt;br&gt;
Food and Beverage&lt;br&gt;
Semiconductor and Electronics&lt;br&gt;
Healthcare&lt;br&gt;
Chemicals, Rubber and Plastics&lt;br&gt;
Metals and Machinery&lt;br&gt;
Others&lt;br&gt;
Automotive holds 43.2% of the market share, as the industry relies heavily on robotic end effectors for welding, painting, and assembling intricate components. The rising transition to EV manufacturing further amplifies demand for specialized grippers and tool changers capable of handling battery assemblies and lightweight materials.&lt;/p&gt;

&lt;p&gt;Breakup By Region:&lt;/p&gt;

&lt;p&gt;North America (United States, Canada)&lt;br&gt;
Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)&lt;br&gt;
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)&lt;br&gt;
Latin America (Brazil, Mexico, Others)&lt;br&gt;
Middle East and Africa&lt;br&gt;
Asia-Pacific holds the leading position with over 42.8% of the global market share in 2025, driven by its strong manufacturing base across China, Japan, and South Korea, rapid industrial automation, expanding e-commerce infrastructure, and government-backed smart factory and Industry 4.0 initiatives.&lt;/p&gt;

&lt;p&gt;Recent News and Developments in the Robot End Effector Market&lt;/p&gt;

&lt;p&gt;February 2025: TESOLLO, a prominent maker of robot grippers based in South Korea, unveiled the Delto Gripper-5 Finger (DG-5F), an advanced robotic hand designed for humanoid robots. The product featured 20 degrees of movement, five independently functioning fingers, and four joints closely replicating human hand mechanics, with commercial availability beginning March 2025.&lt;br&gt;
January 2025: Piab, a global leader in robotic equipment, broadened its product range to include magnetic grippers designed to enhance handling and assembly processes by providing stable and efficient gripping and movement of metal parts across industrial environments.&lt;br&gt;
January 2025: Shadow Robot teamed up with Google DeepMind to develop the DEX-EE, a cutting-edge robotic hand built for real-world machine learning applications. The product featured ultra-quick sensor arrays providing numerous tactile detection lines for every finger, delivering comprehensive sensory data to support advanced dexterous manipulation.&lt;br&gt;
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.&lt;/p&gt;

&lt;p&gt;About Us:&lt;/p&gt;

&lt;p&gt;IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.&lt;/p&gt;

&lt;p&gt;Contact Us:&lt;/p&gt;

&lt;p&gt;IMARC Group&lt;/p&gt;

&lt;p&gt;134 N 4th St. Brooklyn, NY 11249, USA&lt;/p&gt;

&lt;p&gt;Email: &lt;a href="mailto:sales@imarcgroup.com"&gt;sales@imarcgroup.com&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Tel No: (D) +91 120 433 0800&lt;/p&gt;

&lt;p&gt;United States: +1-201-971-6302&lt;/p&gt;

</description>
    </item>
    <item>
      <title>Blood Culture Test Market Size, Share and Growth Forecast 2026-2034</title>
      <dc:creator>Rohit Pujari</dc:creator>
      <pubDate>Mon, 16 Nov 2026 09:25:11 +0000</pubDate>
      <link>https://springbuilders.dev/rohit_pujari_7f35d57dfc70/blood-culture-test-market-size-share-and-growth-forecast-2026-2034-beo</link>
      <guid>https://springbuilders.dev/rohit_pujari_7f35d57dfc70/blood-culture-test-market-size-share-and-growth-forecast-2026-2034-beo</guid>
      <description>&lt;p&gt;Market Overview:&lt;/p&gt;

&lt;p&gt;According to IMARC Group’s latest research publication, “Blood Culture Test Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034”, The global blood culture test market size reached USD 5.85 Billion in 2025 and is projected to reach USD 11.01 Billion by 2034, growing at a CAGR of 6.91% during 2026-2034.&lt;/p&gt;

&lt;p&gt;This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.&lt;/p&gt;

&lt;p&gt;How AI and Automation Are Reshaping the Blood Culture Test Market&lt;/p&gt;

&lt;p&gt;Consumables dominate the product landscape with a 60.4% share in 2025, driven by the high-frequency, recurring purchase of blood culture media, assay kits, and accessories at every testing cycle across hospital and reference laboratories worldwide.&lt;br&gt;
Bacterial infections lead application demand at 70.2% in 2025, sustained by high clinical volumes of suspected sepsis and bacteremia cases requiring prompt diagnostic confirmation to guide targeted antibiotic therapy.&lt;br&gt;
North America commands 39.6% of global market share, supported by well-established healthcare infrastructure, comprehensive insurance coverage, and early adoption of automated blood culture platforms under stringent CLIA-regulated laboratory quality standards.&lt;br&gt;
In March 2026, data presented at the Society of Critical Care Medicine’s Critical Care Congress revealed that widespread implementation of Cytovale’s IntelliSep rapid sepsis diagnostic test was associated with a 19% relative reduction in sepsis mortality across multiple hospital networks, with blood culture utilization remaining above 90% for confirmed sepsis patients.&lt;br&gt;
In September 2026, researchers validated the Sepsis ImmunoScore AI tool for identifying and predicting sepsis within 24 hours of patient assessment, demonstrating high diagnostic accuracy in a study enrolling hospitalized adults with suspected infection identified through a blood culture order.&lt;br&gt;
Download a sample PDF of this report: &lt;a href="https://www.imarcgroup.com/blood-culture-test-market/requestsample"&gt;https://www.imarcgroup.com/blood-culture-test-market/requestsample&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Key Trends in the Blood Culture Test Market&lt;br&gt;
Integration of Molecular Diagnostics with Traditional Culture Methods: Laboratories are increasingly pairing molecular technologies such as PCR and PNA-FISH with conventional culture confirmation to shorten time-to-pathogen-identification while retaining the clinical reliability of culture-based susceptibility testing. Culture-based technology currently accounts for 66.5% of the technology segment, confirming that it remains the clinical benchmark, while molecular and proteomic platforms are growing rapidly as complementary layers within integrated diagnostic workflows.&lt;br&gt;
Rising Adoption of AI-Powered Pathogen Detection Platforms: AI-powered software is being deployed to interpret blood culture growth curves in real time, flagging clinically significant positive cultures faster than manual review. In September 2026, the Sepsis ImmunoScore AI tool demonstrated high accuracy for identifying and predicting sepsis within 24 hours by analyzing blood samples drawn within 6 hours of the first blood culture order. Meanwhile, Day Zero Diagnostics’ Keynome gAST system, developed in collaboration with Oxford Nanopore Technologies, enables culture-free, same-day organism identification by analyzing bacterial whole genomes extracted directly from patient blood, delivering results with over 90% accuracy in treatment matching.&lt;br&gt;
Expansion of Automated Blood Culture Systems in Emerging Markets: Hospitals across Asia Pacific and Latin America are scaling automated blood culture systems to manage rising infection caseloads. Asia Pacific accounts for 20.7% of global market share in 2025 and is growing rapidly on the back of government healthcare infrastructure investment and increasing sepsis detection awareness across China, India, and Southeast Asia. Latin America, contributing 8.1% of global market share, is seeing gradual but consistent diagnostic infrastructure expansion.&lt;br&gt;
Demand Growth from Hospital Laboratories and Reference Settings: Hospital laboratories lead end-user demand at 53.8% in 2025, driven by the need to process rapidly growing volumes of blood culture samples generated by routine post-operative monitoring protocols, catheter-associated bloodstream infection surveillance, and intensive care unit management. Reference laboratories represent an additional high-volume segment as healthcare networks centralize complex microbiology testing.&lt;br&gt;
Rapid Sepsis Panels Gaining Traction in Emergency Settings: Demand is growing for near-patient, rapid diagnostic panels that shorten the diagnostic window for suspected bloodstream infections in emergency departments and intensive care units. In March 2026, Immunexpress presented new data at the SCCM Critical Care Congress on its SeptiCyte RAPID test, which delivers a clinically actionable result within one hour, approximately 12 to 24 hours ahead of standard blood culture results, helping guide earlier clinical decision-making and potentially reducing mortality for time-critical sepsis patients.&lt;br&gt;
We explore the factors propelling the blood culture test market growth, including technological advancements, consumer behaviors, and regulatory changes.&lt;/p&gt;

&lt;p&gt;Growth Factors in the Blood Culture Test Market&lt;br&gt;
Rising Global Incidence of Sepsis and Bloodstream Infections: The World Health Organization estimates that sepsis affects tens of millions of patients annually, with a disproportionate share occurring in critical care and neonatal units where rapid pathogen identification directly influences survival outcomes. As antimicrobial resistance complicates empirical treatment choices, clinicians increasingly rely on culture-confirmed diagnosis to select effective, narrow-spectrum therapy rather than broad-spectrum antibiotics administered on suspicion alone, sustaining high and consistent demand for blood culture testing.&lt;br&gt;
Growing Burden of Hospital-Acquired Infections (HAIs): Surgical site infections and catheter-associated bloodstream infections remain among the most common HAIs, requiring laboratories to process growing volumes of blood culture samples as part of standard post-operative monitoring protocols. National infection-surveillance agencies are tightening reporting requirements for HAI rates, indirectly reinforcing hospital investment in faster and more sensitive blood culture testing infrastructure across surgical and intensive care units.&lt;br&gt;
Advancements in Automated Diagnostic Technology: Automated blood culture systems using advanced sensors and software algorithms are reducing time-to-detection and improving diagnostic accuracy versus manual methods. The conventional testing segment leads at 65.4% in 2025, but automated platforms are growing above the market average as continuous-monitoring instruments can flag positive cultures within hours rather than days, allowing clinicians to narrow antimicrobial therapy earlier and reduce average hospital length of stay for bloodstream infection patients.&lt;br&gt;
Expanding Geriatric and Immunocompromised Patient Pool: An aging global population with rising rates of diabetes, cancer, and chronic conditions faces elevated bloodstream infection risk, increasing the pool of patients requiring blood culture diagnostics as part of routine clinical care. Elderly and immunocompromised patients undergoing chemotherapy, dialysis, or transplant care require frequent bloodstream infection monitoring, generating recurring testing demand across oncology and nephrology departments that strengthens the structural baseline for the market.&lt;br&gt;
Government and Institutional Infection Control Mandates: Infection-control programs at national and institutional levels are mandating routine blood culture surveillance across surgical and intensive care units. The North American market’s leadership at 39.6% is in part a product of the CLIA-regulated laboratory quality standards framework that enforces standardized turnaround-time benchmarks, driving ongoing hospital investment in faster and more compliant automated blood culture platforms.&lt;br&gt;
Leading Companies Operating in the Global Blood Culture Test Industry:&lt;/p&gt;

&lt;p&gt;BIOMÉRIEUX&lt;br&gt;
Abbott&lt;br&gt;
Danaher Corporation&lt;br&gt;
Bruker&lt;br&gt;
Siemens Healthineers AG&lt;br&gt;
Blood Culture Test Market Report Segmentation:&lt;/p&gt;

&lt;p&gt;Breakup By Testing Method:&lt;/p&gt;

&lt;p&gt;Conventional&lt;br&gt;
Automated&lt;br&gt;
Conventional testing accounts for the majority of shares at 65.4% due to its widespread adoption across established hospital laboratory networks and its role as the clinical benchmark for generating viable isolates required for downstream antimicrobial susceptibility testing.&lt;/p&gt;

&lt;p&gt;Breakup By Product:&lt;/p&gt;

&lt;p&gt;Consumables&lt;br&gt;
Blood Culture Media&lt;br&gt;
Assay Kits and Reagents&lt;br&gt;
Blood Culture Accessories&lt;br&gt;
Instruments&lt;br&gt;
Automated Blood Culture Systems&lt;br&gt;
Supporting Laboratory Equipment&lt;br&gt;
Software and Services&lt;br&gt;
Consumables dominate the market at 60.4% owing to the recurring, high-volume purchase of blood culture media, assay kits, and reagents consumed at every testing cycle across hospital and reference laboratories worldwide.&lt;/p&gt;

&lt;p&gt;Breakup By Technology:&lt;/p&gt;

&lt;p&gt;Culture-Based Technology&lt;br&gt;
Molecular Technology (Microarray, PCR, PNA-FISH)&lt;br&gt;
Proteomic Technology&lt;br&gt;
Others&lt;br&gt;
Culture-based technology leads at 66.5% as it remains the clinical standard for detecting and identifying bacterial and fungal pathogens in blood samples, offering high sensitivity and the ability to generate viable isolates for downstream antimicrobial susceptibility testing.&lt;/p&gt;

&lt;p&gt;Breakup By Application:&lt;/p&gt;

&lt;p&gt;Bacterial Infections&lt;br&gt;
Fungal Infections&lt;br&gt;
Mycobacterial Infections&lt;br&gt;
Bacterial infections lead at 70.2% owing to the high clinical volume of suspected sepsis and bacteremia cases requiring prompt diagnostic confirmation to guide targeted antibiotic therapy across hospital and emergency care settings.&lt;/p&gt;

&lt;p&gt;Breakup By End User:&lt;/p&gt;

&lt;p&gt;Hospital Laboratories&lt;br&gt;
Reference Laboratories&lt;br&gt;
Research Laboratories&lt;br&gt;
Others&lt;br&gt;
Hospital laboratories account for the leading share at 53.8% due to the high volume of inpatient blood culture testing requirements across surgical units, intensive care departments, and post-operative monitoring programs.&lt;/p&gt;

&lt;p&gt;Breakup By Region:&lt;/p&gt;

&lt;p&gt;North America (United States, Canada)&lt;br&gt;
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)&lt;br&gt;
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)&lt;br&gt;
Latin America (Brazil, Mexico, Others)&lt;br&gt;
Middle East and Africa&lt;br&gt;
North America enjoys the leading position at 39.6% owing to its expansive network of hospitals and diagnostic laboratories, strong insurance penetration, and early adoption of automated blood culture systems under CLIA-regulated laboratory quality standards.&lt;/p&gt;

&lt;p&gt;Recent News and Developments in the Blood Culture Test Market&lt;/p&gt;

&lt;p&gt;March 2026: Data presented at the Society of Critical Care Medicine’s Critical Care Congress demonstrated that widespread implementation of Cytovale’s IntelliSep rapid sepsis diagnostic was associated with a 19% relative reduction in sepsis mortality across multiple hospital networks, while blood culture utilization remained above 90% for confirmed sepsis patients, reinforcing the complementary role of rapid diagnostics alongside traditional culture-based testing.&lt;br&gt;
March 2026: Immunexpress presented new clinical data on its SeptiCyte RAPID test at the SCCM Critical Care Congress, showing 91% alignment with physician-adjudicated, blood-culture-positive sepsis cases across a retrospective analysis of more than a thousand patients. The test delivers a clinically actionable result within one hour, approximately 12 to 24 hours ahead of standard blood culture results, supporting earlier therapeutic decision-making in time-critical sepsis cases.&lt;br&gt;
2025: bioMerieux received FDA 510(k) clearance for the BacT/ALERT VIRTUO automated blood culture system, marking it as the first continuously-monitoring blood culture microbial detection system to offer “Load and Go” technology, designed to streamline laboratory workflows and reduce manual handling steps in automated blood culture processing.&lt;br&gt;
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.&lt;/p&gt;

&lt;p&gt;About Us:&lt;/p&gt;

&lt;p&gt;IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.&lt;/p&gt;

&lt;p&gt;Contact Us:&lt;/p&gt;

&lt;p&gt;IMARC Group&lt;/p&gt;

&lt;p&gt;134 N 4th St. Brooklyn, NY 11249, USA&lt;/p&gt;

&lt;p&gt;Email: &lt;a href="mailto:sales@imarcgroup.com"&gt;sales@imarcgroup.com&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Tel No: (D) +91 120 433 0800&lt;/p&gt;

&lt;p&gt;United States: +1-201-971-6302&lt;/p&gt;

</description>
    </item>
    <item>
      <title>Veterinary Vaccines Market Growth: Disease Prevention Demand &amp; Industry Outlook 2026-2034</title>
      <dc:creator>Rohit Pujari</dc:creator>
      <pubDate>Thu, 29 Oct 2026 05:17:25 +0000</pubDate>
      <link>https://springbuilders.dev/rohit_pujari_7f35d57dfc70/veterinary-vaccines-market-growth-disease-prevention-demand-industry-outlook-2026-2034-l24</link>
      <guid>https://springbuilders.dev/rohit_pujari_7f35d57dfc70/veterinary-vaccines-market-growth-disease-prevention-demand-industry-outlook-2026-2034-l24</guid>
      <description>&lt;p&gt;&lt;a href="https://springbuilders.dev/images/OR9J1xsRLhBJpX7m47Zn_u8EEOZjFn6IE96CiHfRHxU/rt:fit/w:800/g:sm/q:0/mb:500000/ar:1/aHR0cHM6Ly9zcHJp/bmdidWlsZGVycy5k/ZXYvdXBsb2Fkcy9h/cnRpY2xlcy9yd3hk/YnBxMm9hY3ljeXoz/d3h3OC5wbmc" class="article-body-image-wrapper"&gt;&lt;img src="https://springbuilders.dev/images/OR9J1xsRLhBJpX7m47Zn_u8EEOZjFn6IE96CiHfRHxU/rt:fit/w:800/g:sm/q:0/mb:500000/ar:1/aHR0cHM6Ly9zcHJp/bmdidWlsZGVycy5k/ZXYvdXBsb2Fkcy9h/cnRpY2xlcy9yd3hk/YnBxMm9hY3ljeXoz/d3h3OC5wbmc" alt="Image description" width="800" height="447"&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Market Overview:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;According to IMARC Group’s latest research publication, &lt;/span&gt;&lt;strong&gt;“Veterinary Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034”&lt;/strong&gt;&lt;span&gt;, The global veterinary vaccines market reached USD 15.82 Billion in 2025 and is projected to reach USD 30.67 Billion by 2034, growing at a CAGR of 7.41% during 2026-2034.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How mRNA and Novel Platforms Are Reshaping the Future of the Veterinary Vaccines Market&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;mRNA veterinary vaccine platforms are enabling rapid antigen design and customized immunity, with CD Bioparticles launching an advanced animal mRNA vaccine platform in January 2026 offering sequence optimization, mRNA synthesis, lipid nanoparticle formulation, and preclinical testing capabilities.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;In May 2026, the Committee for Veterinary Medicinal Products at the European Medicines Agency recommended marketing authorization for Nobivac NXT HCPChFeLV, marking the first veterinary vaccine to use self-amplifying RNA technology, validating the integration of RNA platforms into mainstream veterinary medicine.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;
&lt;span&gt;Livestock vaccines dominate the market at &lt;/span&gt;&lt;strong&gt;63.8%&lt;/strong&gt;&lt;span&gt; share, reflecting high demand across commercial poultry, swine, cattle, and aquaculture sectors where disease prevention is directly tied to food security and trade compliance.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;span&gt;North America leads global market share at &lt;/span&gt;&lt;strong&gt;36.4%&lt;/strong&gt;&lt;span&gt;, driven by the world’s highest companion animal vaccination compliance rates, comprehensive livestock vaccine infrastructure, and the highest per-animal veterinary expenditure of any major market.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;span&gt;Intranasal vaccine delivery is the fastest-growing administration route, with an estimated growth of approximately &lt;/span&gt;&lt;strong&gt;8.2%&lt;/strong&gt;&lt;span&gt;, supported by needle-free delivery adoption in canine cough vaccines, bovine intranasal respiratory vaccines, and poultry spray vaccination programs.&lt;/span&gt;
&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Download a sample PDF of this report:&lt;/strong&gt;&lt;a href="https://www.imarcgroup.com/veterinary-vaccines-market/requestsample"&gt; &lt;span&gt;https://www.imarcgroup.com/veterinary-vaccines-market/requestsample&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;Key Trends in the Veterinary Vaccines Market&lt;/strong&gt;&lt;/h3&gt;

&lt;ul&gt;
&lt;li&gt;
&lt;strong&gt;mRNA Veterinary Vaccine Platform Commercialisation Creating a Technology Revolution:&lt;/strong&gt;&lt;span&gt; The commercialization of mRNA vaccine platforms for animals enables rapid, customizable, and highly precise vaccine development. In January 2026, CD Bioparticles introduced an advanced animal mRNA vaccine platform with capabilities across sequence optimization, LNP formulation, and preclinical testing, enabling faster responses to emerging pathogens and improving immune protection across both livestock and companion animal categories.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Digital Health Integration Improving Companion Animal Vaccination Compliance:&lt;/strong&gt;&lt;span&gt; Digital health tools including apps, veterinary telehealth platforms, and automated reminders are significantly improving vaccination adherence in companion animals. These tools improve clinic revenue, streamline record-keeping, and increase owner engagement, pushing non-core vaccine uptake in markets such as North America and Western Europe, where the digital veterinary health integration opportunity represents an adjacent revenue pool estimated at USD 500 Million to USD 1 Billion.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Aquaculture Vaccine Innovation Expanding to New Species and Delivery Methods:&lt;/strong&gt;&lt;span&gt; Aquaculture vaccine development is expanding beyond established fish species into shrimp, tilapia, and new aquatic species using alternative delivery methods such as oral and immersion vaccines. This trend is driven by rising aquaculture production globally, reduced antibiotic use mandates, and a growing recognition that shrimp aquaculture alone represents the most commercially attractive untapped segment in veterinary vaccinology, with no commercially available vaccine despite decades of research.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Personalised and Precision Immunology Advancing Veterinary Oncology Vaccines:&lt;/strong&gt;&lt;span&gt; Genetic, molecular, and immune profiling is enabling the development of tailored oncology vaccines for companion animals. This precision approach delivers more effective, targeted cancer prevention and treatment with reduced off-target effects, representing one of the fastest-growing innovation frontiers in companion animal healthcare and a key revenue driver for premium veterinary vaccine providers.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Companion Animal Humanisation Driving Non-Core Vaccine Premiumization:&lt;/strong&gt;&lt;span&gt; As pet owners increasingly treat animals as family members, demand is rising for non-core vaccines covering Lyme disease, leptospirosis L4, and canine influenza. The United States has approximately &lt;/span&gt;&lt;strong&gt;70 million&lt;/strong&gt;&lt;span&gt; domestic dogs and &lt;/span&gt;&lt;strong&gt;74 million&lt;/strong&gt;&lt;span&gt; domestic cats, and this large companion animal base is generating strong demand for preventive healthcare products. European non-core vaccine penetration currently stands below &lt;/span&gt;&lt;strong&gt;30-40%&lt;/strong&gt;&lt;span&gt; of North American levels, representing a USD 400 to 600 Million incremental opportunity.&lt;/span&gt;
&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;span&gt;The &lt;/span&gt;&lt;a href="https://www.imarcgroup.com/veterinary-vaccines-market"&gt;&lt;span&gt;veterinary vaccines market report&lt;/span&gt;&lt;/a&gt;&lt;span&gt; provides a comprehensive overview of the industry. This analysis is essential for stakeholders aiming to navigate the complexities of the biochar market and capitalize on emerging opportunities.&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;Growth Factors in the Veterinary Vaccines Market&lt;/strong&gt;&lt;/h3&gt;

&lt;ul&gt;
&lt;li&gt;
&lt;strong&gt;Rising Pet Ownership Globally Accelerating Vaccination Demand:&lt;/strong&gt;&lt;span&gt; The United States alone is home to the world’s largest populations of both domesticated dogs and cats. This scale of pet ownership, combined with a cultural shift toward treating animals as family members, directly drives demand for both core and non-core companion animal vaccines, expanding vaccine compliance programs and boosting premium vaccine adoption, particularly in North America and Western Europe.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Food Security Imperatives Sustaining Livestock Vaccine Investment:&lt;/strong&gt;&lt;span&gt; Preventing infectious disease in cattle, poultry, and swine is a direct contributor to global food supply stability and international meat export compliance. Governments and commercial producers worldwide are investing in mandatory and preventive livestock vaccination programs, keeping demand structurally elevated for vaccines across poultry, swine, and cattle segments, which collectively represent livestock vaccines’ &lt;/span&gt;&lt;strong&gt;63.8%&lt;/strong&gt;&lt;span&gt; market share.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;mRNA and Novel Platform Technologies Expanding the Vaccine Development Pipeline:&lt;/strong&gt;&lt;span&gt; In February 2024, the University of Pennsylvania School of Veterinary Medicine launched the mRNA Research Initiative to accelerate the development of veterinary mRNA-based vaccines and host-directed therapies. This initiative enhances adoption of novel vaccine platforms, enabling faster response to emerging animal diseases and more precise immunity, and represents a direct investment in the next generation of premium-priced veterinary vaccine products.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Government-Funded Livestock Vaccination Programs in Asia Pacific Driving Scale:&lt;/strong&gt;&lt;span&gt; Asia Pacific holds &lt;/span&gt;&lt;strong&gt;24.1%&lt;/strong&gt;&lt;span&gt; of the global market and is the fastest-growing region, driven by India’s government-funded livestock vaccination programs and China’s evolving commercial livestock vaccination infrastructure. Government procurement mandates create large, predictable vaccine demand and accelerate market penetration in countries where private veterinary infrastructure is still developing.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;Zoonotic Disease Awareness Creating Structural Demand for Canine Rabies Vaccination:&lt;/strong&gt;&lt;span&gt; Rabies is entirely preventable through vaccination, and control programs require immunizing over &lt;/span&gt;&lt;strong&gt;70%&lt;/strong&gt;&lt;span&gt; of the canine population to halt disease transmission at the reservoir level. This coverage threshold creates ongoing, large-volume demand for veterinary rabies vaccines globally, underpinning a durable demand floor particularly in developing markets where canine rabies remains a public health priority.&lt;/span&gt;
&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Leading Companies Operating in the Global Veterinary Vaccines Industry:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;Zoetis Inc.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Merck and Co., Inc.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Boehringer Ingelheim International GmbH&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Elanco&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Virbac&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Veterinary Vaccines Market Report Segmentation:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Breakup By Vaccine Type:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;Livestock Vaccines&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Companion Animal Vaccines&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;span&gt;Livestock vaccines account for the majority of market share at &lt;/span&gt;&lt;strong&gt;63.8%&lt;/strong&gt;&lt;span&gt;, driven by the high volume of doses administered across commercial poultry, swine, cattle, and aquaculture sectors and the direct link between livestock health and food production economics.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Breakup By Technology:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;Attenuated Live Vaccines&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Inactivated Vaccines&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Toxoid Vaccines&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Recombinant Vaccines&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Others&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Breakup By Route of Administration:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;Subcutaneous&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Intramuscular&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Intranasal&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;span&gt;Subcutaneous administration leads the segment at &lt;/span&gt;&lt;strong&gt;46.8%&lt;/strong&gt;&lt;span&gt; due to its established suitability for killed and inactivated vaccine delivery across companion animals, cattle, and equine categories, generating the slow antigen release that optimizes immune response.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Breakup By Distribution Channel:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;Veterinary Hospitals&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Veterinary Clinics&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Pharmacies and Drug Stores&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Others&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Breakup By Region:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;North America (United States, Canada)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Latin America (Brazil, Mexico, Others)&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Middle East and Africa&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;span&gt;North America enjoys the leading position with &lt;/span&gt;&lt;strong&gt;36.4%&lt;/strong&gt;&lt;span&gt; of the global market owing to well-established companion animal vaccination compliance programs, comprehensive livestock vaccine licensing infrastructure, and the highest per-animal veterinary expenditure of any major market globally.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Recent News and Developments in the Veterinary Vaccines Market&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;
&lt;strong&gt;January 2026:&lt;/strong&gt;&lt;span&gt; CD Bioparticles introduced an advanced animal mRNA vaccine platform to accelerate the development of innovative, customized veterinary vaccines, offering capabilities across sequence optimization, mRNA synthesis, lipid nanoparticle formulation, and preclinical testing.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;May 2026:&lt;/strong&gt;&lt;span&gt; The Committee for Veterinary Medicinal Products at the European Medicines Agency recommended marketing authorization for Nobivac NXT HCPChFeLV, making it the first veterinary vaccine to use self-amplifying RNA technology and marking a landmark integration of RNA platforms into mainstream veterinary medicine.&lt;/span&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;strong&gt;November 2025:&lt;/strong&gt;&lt;span&gt; Zoetis launched Vanguard Recombishield in the United States, an injectable recombinant vaccine designed to protect companion animals against Bordetella bronchiseptica, offering effective protection with a comfortable administration experience that minimizes pain, swelling, and sensitivity for the animal.&lt;/span&gt;
&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Note:&lt;/strong&gt; &lt;em&gt;&lt;span&gt;If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;About Us:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Contact Us:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;IMARC Group&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;134 N 4th St. Brooklyn, NY 11249, USA&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Email: sales@imarcgroup.com&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Tel No: (D) +91 120 433 0800&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;United States: +1-201-971-6302&lt;/span&gt;&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

</description>
    </item>
  </channel>
</rss>
